|
Variables
|
Patients
|
EGFR mutation
|
EGFR copy number
|
|---|
|
n = 416
|
Mutant
|
Wild
| |
FISH (+)
|
FISH (−)
| |
|---|
|
No.
|
%
|
n = 169
|
n = 247
|
P value
|
n = 167
|
n = 249
|
P value
|
|---|
|
Age groups
|
|
≤ 60
|
264
|
63.5
|
108 (63.9)
|
156 (63.2)
|
0.918
|
108 (64.7)
|
156 (62.7)
|
0.680
|
|
> 60
|
152
|
36.5
|
61 (36.1)
|
91 (36.8)
|
59 (35.3)
|
93 (37.3)
|
|
Gender
|
|
Male
|
253
|
60.8
|
86 (50.9)
|
167 (67.6)
|
< 0.001
|
92 (55.1)
|
161 (64.7)
|
0.052
|
|
Female
|
163
|
39.2
|
83 (49.1)
|
80 (32.4)
|
75 (44.9)
|
88 (35.3)
|
|
Smoking status
|
|
Never-smoker
|
269
|
64.7
|
129 (76.3)
|
140 (56.7)
|
< 0.001
|
116 (69.5)
|
155 (62.2)
|
0.142
|
|
Smoker
|
147
|
35.3
|
40 (23.7)
|
107 (43.3)
|
51 (30.5)
|
94 (37.8)
|
|
Histology
|
|
ADC
|
336
|
80.8
|
154 (91.1)
|
182 (73.7)
|
< 0.001
|
138 (82.6)
|
198 (79.5)
|
0.449
|
|
Non-ADC
|
80
|
19.2
|
15 (8.9)
|
65 (26.3)
|
29 (17.4)
|
51 (20.5)
|
|
Differentiation
|
|
High to medium
|
185
|
44.5
|
92 (54.4)
|
93 (37.7)
|
< 0.001
|
85 (50.9)
|
100 (40.2)
|
0.035
|
|
Low
|
231
|
55.5
|
77 (45.6)
|
154 (62.3)
|
82 (49.1)
|
149 (59.8)
|
|
Disease stage
|
|
Recurrent
|
128
|
30.8
|
55 (32.5)
|
73 (29.6)
|
0.127
|
51 (30.5)
|
77 (30.9)
|
0.926
|
|
IIIb
|
73
|
17.5
|
22 (13.0)
|
51 (20.6)
|
28 (16.8)
|
45 (18.1)
|
|
IV
|
215
|
51.7
|
92 (54.4)
|
123 (49.8)
|
88 (52.7)
|
127 (51.0)
|
|
Clinical response
|
|
CR + PR
|
93
|
22.4
|
68 (40.2)
|
25 (10.1)
|
< 0.001
|
53 (31.7)
|
40 (16.1)
|
< 0.001
|
|
SD
|
158
|
38.0
|
83 (49.1)
|
75 (30.4)
|
79 (47.3)
|
79 (31.7)
|
|
PD
|
161
|
38.7
|
14 (8.3)
|
147 (59.5)
|
32 (19.2)
|
129 (51.8)
|
|
Unknown
|
4
|
1.0
|
4 (2.4)
|
0 (0.0)
|
3 (1.8)
|
1 (0.4)
|
|
Line of EGFR-TKIs
|
|
First
|
104
|
25.0
|
62 (36.7)
|
42 (17.0)
|
< 0.001
|
48 (28.7)
|
56 (22.5)
|
< 0.001
|
|
Second
|
217
|
52.2
|
107 (63.3)
|
110 (44.5)
|
97 (58.1)
|
120 (48.2)
|
|
Higher
|
95
|
22.8
|
0 (0.0)
|
95 (38.5)
|
22 (13.2)
|
73 (29.3)
|
- Non-adenocarcinoma included squamous-cell carcinoma (n = 58), adenosquamous cell carcinoma (n = 20), and other histology (n = 2)
- ADC adenocarcinoma, FISH fluorescent in situ hybridization, CR complete remission, PR partial remission, SD stable disease, PD progressive disease, TKI, tyrosine kinase inhibitor
